ILARIS, also known by its generic name canakinumab, is a prescription medication used in the treatment of various auto-inflammatory syndromes. It is a type of biologic medication, specifically a monoclonal antibody, that targets and neutralizes interleukin-1 beta (IL-1β), a protein in the body that plays a key role in inflammation and immune responses. By inhibiting the action of IL-1β, ILARIS effectively reduces inflammation and helps manage symptoms associated with conditions such as Cryopyrin-Associated Periodic Syndromes (CAPS), Systemic Juvenile Idiopathic Arthritis (SJIA), and other rare diseases. Administered through subcutaneous injection, ILARIS is often prescribed when other treatments have not been effective, offering a targeted approach to managing complex auto-inflammatory conditions.